Molnupiravir was studied in a randomized, double-blind, placebo-controlled clinical trial of 1433 nonhospitalized patients ≥ 18 years of age with mild to moderate COVID-19 at high risk for progression to severe COVID-19 and / or hospitalization and who had not received a COVID-19 vaccine.